Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill targets leukemia's genetic weak spot in phase 3 trial

NCT ID NCT07223814

First seen Nov 03, 2025 · Last updated May 20, 2026 · Updated 26 times

Summary

This study tests whether adding the experimental drug bleximenib to standard chemotherapy improves outcomes for adults with newly diagnosed acute myeloid leukemia (AML) that has a KMT2A rearrangement or NPM1 mutation. Bleximenib blocks a protein interaction that helps leukemia cells survive. About 875 participants will receive either bleximenib or a placebo alongside chemo, followed by maintenance therapy. The main goal is to see if the drug extends the time without cancer returning.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • DE-Ulm-UNIKLINKULM

    RECRUITING

    Ulm, Germany

    Contact

  • NL-Breda-AMPHIA

    RECRUITING

    Breda, Netherlands

    Contact

  • NL-Den Haag-HAGA

    RECRUITING

    The Hague, Netherlands

    Contact

  • NL-Eindhoven-MAXIMAMC

    RECRUITING

    Eindhoven, Netherlands

    Contact

  • NL-Leeuwarden-FRISIUSMC

    RECRUITING

    Leeuwarden, Netherlands

    Contact

  • NL-Nieuwegein-ANTONIUS

    RECRUITING

    Nieuwegein, Netherlands

    Contact

  • NL-Rotterdam-ERASMUCMC

    RECRUITING

    Rotterdam, Netherlands

    Contact

  • US-Cincinnati OH-CINCY

    RECRUITING

    Cincinnati, Ohio, 45219, United States

    Contact

Conditions

Explore the condition pages connected to this study.